Report: Cancer Vaccines: Aim and Shoot TOC

1. Executive Summary

2. About Cancer Highlights

3. Methodologies

4. Table of Contents

4.1 List of Figures
4.2 List of Tables

5. How to Use this Report

6. Cancer Vaccines Types

7. The Cancer Genome Project and Cancer Vaccine Drug Targets

7.1 Cancer Vaccine Drug Targets Present in the Cancer Gene Census and in the Catalogue Somatic Mutations in Cancer

8. Protein Expression Profiles of Cancer Vaccine Drug Targets in Human

8.1 Expression in Normal Tissues and Cancer Tissues
8.2 Expression in Human Cancer Cell Lines and Primary Cells

9. Pathway Analysis of Cancer Vaccine Drugs

10. Protein-Protein Interactions Among Identified Cancer Vaccine Drug Targets

11. Available Biological Structure Data on Cancer Vaccine Drug Targets

12. Drug Target Profiles of Cancer Vaccine Drug Targets in Oncology

12.1.1 Acid phosphatase activity
12.1.2 Carboxypeptidase activity
12.1.3 Catalytic activity
12.1.4 Cell adhesion molecule activity
12.1.5 Chaperone activity
12.1.6 Cofactor binding
12.1.7 Complement activity
12.1.8 Cytokine activity
12.1.9 DNA binding
12.1.10 DNA topoisomerase activity
12.1.11 DNA-directed DNA polymerase activity
12.1.12 Growth factor activity
12.1.13 Hormone activity
12.1.14 Hydrolase activity
12.1.15 Intracellular ligand-gated ion channel activity
12.1.16 Kinase binding
12.1.17 Kinase regulator activity
12.1.18 Metallopeptidase activity
12.1.19 MHC class I receptor activity
12.1.20 Molecular function unknown
12.1.21 Oxidoreductase activity
12.1.22 Peptidase activity
12.1.23 Peptide hormone
12.1.24 Protein binding
12.1.25 Protein serine/threonine kinase activity
12.1.26 Protein-tyrosine kinase activity
12.1.27 Receptor activity
12.1.28 Receptor binding
12.1.29 Receptor signaling complex scaffold activity
12.1.30 RNA-directed DNA polymerase activity
12.1.31 Serine-type peptidase activity
12.1.32 T cell receptor activity
12.1.33 Transcription factor activity
12.1.34 Transmembrane receptor activity
12.1.35 Transmembrane receptor protein tyrosine kinase activity
12.1.36 Transporter activity
12.1.37 Viral Protein

13. The Drug-Protein Interactome of Cancer Vaccines

14. The Progression and Maturity of Cancer Vaccine Drug Target Combinations

14.1 Target Profiles of Cancer Vaccines in Pre-Registration or on the Market
14.2 New Cancer Vaccine Target Combinations in Phase III Clinical Development
14.3 New Cancer Vaccine Target Combinations in Phase II Clinical Development
14.4 New Cancer Vaccine Target Combinations Phase I Clinical Development
14.5 New Cancer Vaccine Target Combinations in Preclinical Development
14.6 Development Profiles of All Identified Cancer VaccineTarget Combinations

15. Cancer Vaccine Drug Target Mix by Cancer Indication

15.1 Anal Dysplasia
15.2 Basal Cell Cancer
15.3 Bladder Cancer
15.4 Bone Cancer
15.5 Brain Cancer
15.6 Breast Cancer
15.7 Cervical Cancer
15.8 Cervical Dysplasia
15.9 Chemotherapy-Induced Bone Marrow Injury
- 15.9.1 Chemotherapy-Induced Neutropenia
15.10 Colorectal Cancer
15.11 Gastrointestinal Cancer
15.12 Head and Neck Cancer
15.13 Leukemia
- 15.13.1 Acute Myelogenous Leukemia
- 15.13.2 Chronic Lymphocytic Leukemia
- 15.13.3 Chronic Myelogenous Leukemia
15.14 Liver Cancer
15.15 Lung Cancer
- 15.15.1 Non-Small Cell Lung Cancer
- 15.15.2 Small Cell Lung Cancer
15.16 Lymphoma
- 15.16.1 B-Cell Lymphoma
- 15.16.2 Non-Hodgkin' s Lymphoma
- 15.16.3 T-Cell Lymphoma
15.17 Myelodysplastic Syndrome
15.18 Myeloma
15.19 Nasopharyngeal Cancer
15.20 Oesophageal Cancer
15.21 Ovarian Cancer
15.22 Pancreatic Cancer
15.23 Prostate Cancer
15.24 Renal Cancer
15.25 Sarcoma
15.26 Skin Cancer
- 15.26.1 Melanoma
15.27 Thyroid Cancer

16. Cancer Vaccine Drugs and Their Targets by Companies

16.1 Australia
16.2 Canada
16.3 China
16.4 Denmark
16.5 France
16.6 Germany
16.7 India
16.8 Israel
16.9 Italy
16.10 Japan
16.11 Netherlands
16.12 Norway
16.13 South Korea
16.14 Switzerland
16.15 United Kingdom
16.16 USA
16.17 Non-Industrial Bodies

17. Disclaimer

18. Drug Index

19. Company Index

4.1 List of Figures

Figure 1: Distribution of Compound Types Among Cancer Vaccines
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Protein-Protein Interactions Among Cancer Vaccine Drug Targets
Figure 4: The Vaccine-Protein Interactome of Cancer Vaccines
Figure 5: Direct Head-to-Head Targeting Interactome of Cancer Vaccines

4.2 List of Tables

Table 2: Drug Targets of Cancer Vaccines Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Available Protein Expression Profiles of Cancer Vaccine Drug Targets
Table 4: Pathway Summary
Table 5: Drug Targets Without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of Cancer Vaccine Targets
Table 7: Pathway Profile According to KEGG of Cancer Vaccine Targets
Table 8: Cancer Vaccines Targeting Major Singaling Pathways
Table 9: Protein-Protein Interactions Among Cancer Vaccine Drug Targets
Table 10: Number of Available Biological Structures on Cancer Vaccine Targets
Table 11: Overview of Drug Target Profile Themes
Table 12: Vaccine-Protein Target Clusters in the Cancer Vaccine Drug Target Interactome
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by Developmental Stage
Table 14: Target Profiles of Cancer Vaccines in Pre-Registration or on the Market
Table 15: New Cancer Vaccine Drug Target Combinations in Phase III Clinical Development
Table 16: New Cancer Vaccine Target Combinations in Phase II Clinical Development
Table 17 New Cancer Vaccine Target Combinations Phase I Clinical Development
Table 18: New Cancer Vaccine Target Combinations in Preclinical Development
Table 19: Top 5 Pursued Cancer Vaccine Targets
Table 20: The Progression, Maturity and Comptitive Comparison of Cancer Vaccine Target Mixes in Development
Table 21: Number of Cancer Vaccine Drug Target Mixes Reported by Cancer Indication
Table 22: Locating Your Competitors/Peers - Step 1
Table 23: Locating Your Competitors/Peers - Step 2
Table 24: Drug Targets of Cancer Vaccines for the Treatment of Anal Dysplasia According to the Compound Type and Developmental Stage of Vaccine
Table 25: Drug Targets of Cancer Vaccines for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 26: Drug Targets of Cancer Vaccines for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 27: Drug Targets of Cancer Vaccines for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 28: Drug Targets of Cancer Vaccines for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 29: Drug Targets of Cancer Vaccines for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 30: Drug Targets of Cancer Vaccines for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 31: Drug Targets of Cancer Vaccines for the Treatment of Cervical Dysplasia According to the Compound Type and Developmental Stage of Vaccine
Table 32: Drug Targets of Cancer Vaccines for the Treatment of Chemotherapy-Induced Bone Marrow Injury (General) According to the Compound Type and Developmental Stage of Vaccine
Table 33: Drug Targets of Cancer Vaccines for the Treatment of Chemotherapy-Induced Neutropenia According to the Compound Type and Developmental Stage of Vaccine
Table 34: Drug Targets of Cancer Vaccines for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 35: Drug Targets of Cancer Vaccines for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 36: Drug Targets of Cancer Vaccines for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 37: Drug Targets of Cancer Vaccines for the Treatment of Leukemia (General) According to the Compound Type and Developmental Stage of Vaccine
Table 38: Drug Targets of Cancer Vaccines for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Vaccine
Table 39: Drug Targets of Cancer Vaccines for the Treatment of Chronic Lymphocytic Leukemia According to Compound Type and Developmental Stage of Vaccine
Table 40: Drug Targets of Cancer Vaccines for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Vaccine
Table 41: Drug Targets of Cancer Vaccines for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 42: Drug Targets of Cancer Vaccines for the Treatment of Lung Cancer (General) According to the Compound Type and Developmental Stage of Vaccine
Table 43: Drug Targets of Cancer Vaccines for the Treatment of Non Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 44 Drug Targets of Cancer Vaccines for the Treatment of Small Cell Lung According to the Compound Type and Developmental Stage of Vaccine
Table 45: Drug Targets of Cancer Vaccines for the Treatment of Lymphoma (General) According to the Compound Type and Developmental Stage of Vaccine
Table 46: Drug Targets of Cancer Vaccines for the Treatment of B-Cell Lymphoma According to the Compound Type and Developmental Stage of Vaccine
Table 47: Drug Targets of Cancer Vaccines for the Treatment of non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Vaccine
Table 48: Drug Targets of Cancer Vaccines for the Treatment of T-Cell Lymphoma According to the Compound Type and Developmental Stage of Vaccine
Table 49: Drug Targets of Cancer Vaccines for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Vaccine
Table 50: Drug Targets of Cancer Vaccines for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Vaccine
Table 51: Drug Targets of Cancer Vaccines for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 52: Drug Targets of Cancer Vaccines for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 53: Drug Targets of Cancer Vaccines for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 54: Drug Targets of Cancer Vaccines for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 55: Drug Targets of Cancer Vaccines for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 56: Drug Targets of Cancer Vaccines for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 57: Drug Targets of Cancer Vaccines for the Treatment of Sarcoma According to the Compound Type and Developmental Stage of Vaccine
Table 58: Drug Targets of Cancer Vaccines for the Treatment of Skin Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 59: Drug Targets of Cancer Vaccines for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Vaccine
Table 60: Drug Targets of Cancer Vaccines for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Vaccine
Table 61: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Australia
Table 62: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Canada
Table 63: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in China
Table 64: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Denmark
Table 65: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in France
Table 66: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Germany
Table 67: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in India
Table 68: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Israel
Table 69: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Italy
Table 70: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Japan
Table 71: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in the Netherlands
Table 72: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Norway
Table 73: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in South Korea
Table 74: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in Switzerland
Table 75: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in United Kingdom
Table 76: Cancer Vaccines with Drug Target Mix and Developmental Projects by Companies in USA

Table 77: Cancer Vaccines with Drug Target Mix and Developmental Projects by Non-Industrial Bodies